Pediatric chronic spontaneous urticaria: a brief clinician's guide

Area of Science:

• Pediatric Dermatology
• Allergy and Immunology
• Urticaria Pathophysiology

Background:

• Chronic urticaria (CU) presents as wheals/angioedema >6 weeks; spontaneous CU (CSU) lacks triggers.
• CSU affects up to 50% of patients, leading to poor quality of life (QoL) and high healthcare costs.
• Current CSU treatments target mast cell mediators or activators, with limited pediatric-specific data.

Purpose of the Study:

• To provide a practical guide for managing pediatric chronic spontaneous urticaria (CSU).
• To review current treatment options and guidelines for CSU in children.
• To highlight the need for pediatric-specific research and personalized treatment strategies.

Main Methods:

• Review of existing literature and treatment guidelines for chronic spontaneous urticaria.
• Extrapolation of adult treatment data to the pediatric population.
• Discussion of emerging biological treatments and pandemic-related considerations.

Main Results:

• Diagnosis of CSU involves excluding other causes of chronic urticaria.
• Standard therapy involves second-generation antihistamines (sgAHs), with omalizumab as a second-line option.
• Pediatric CSU treatment is largely based on adult data, necessitating reevaluation.

Conclusions:

• Effective pediatric CSU management requires complete symptom control and QoL normalization.
• Current guidelines need updating based on pediatric data and new therapies.
• Future research should focus on personalized treatments and predictive biomarkers for pediatric CSU.